Fig. 2
From: Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?
Plot of net monetary benefit margin over modeled years. NMB Net Monetary Benefit, ΔNMB NMB(identification of 3b patient group)—NMB(direct use of pan-genotype regimen